15 results on '"Cook, Deborah J."'
Search Results
2. Frequency of Screening and SBT Technique Trial - North American Weaning Collaboration (FAST-NAWC): a protocol for a multicenter, factorial randomized trial
- Author
-
Burns, K. E. A., Rizvi, Leena, Cook, Deborah J., Seely, Andrew J. E., Rochwerg, Bram, Lamontagne, Francois, Devlin, John W., Dodek, Peter, Mayette, Michael, Tanios, Maged, Gouskos, Audrey, Kay, Phyllis, Mitchell, Susan, Kiedrowski, Kenneth C., and Hill, Nicholas S.
- Published
- 2019
- Full Text
- View/download PDF
3. Correction to: Project management lessons learned from the multicentre CYCLE pilot randomized controlled trial
- Author
-
McCaskell, Devin S., Molloy, Alexander J., Childerhose, Laura, Costigan, F. Aileen, Reid, Julie C., McCaughan, Magda, Clarke, France, Cook, Deborah J., Rudkowski, Jill C., Farley, Christopher, Karachi, Tim, Rochwerg, Bram, Newman, Anastasia, Fox-Robichaud, Alison, Herridge, Margaret S., Lo, Vincent, Feltracco, Deanna, Burns, Karen E. A., Porteous, Rebecca, Seely, Andrew J. E., Ball, Ian M., Seczek, Amy, and Kho, Michelle E.
- Published
- 2019
- Full Text
- View/download PDF
4. Project management lessons learned from the multicentre CYCLE pilot randomized controlled trial
- Author
-
McCaskell, Devin S., Molloy, Alexander J., Childerhose, Laura, Costigan, F. Aileen, Reid, Julie C., McCaughan, Magda, Clarke, France, Cook, Deborah J., Rudkowski, Jill C., Farley, Christopher, Karachi, Tim, Rochwerg, Bram, Newman, Anastasia, Fox-Robichaud, Alison, Herridge, Margaret S., Lo, Vincent, Feltracco, Deanna, Burns, Karen EA, Porteous, Rebecca, Seely, Andrew J. E., Ball, Ian M., Seczek, Amy, and Kho, Michelle E.
- Published
- 2019
- Full Text
- View/download PDF
5. 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial
- Author
-
Daneman, Nick, Rishu, Asgar H., Pinto, Ruxandra, Aslanian, Pierre, Bagshaw, Sean M., Carignan, Alex, Charbonney, Emmanuel, Coburn, Bryan, Cook, Deborah J., Detsky, Michael E., Dodek, Peter, Hall, Richard, Kumar, Anand, Lamontagne, Francois, Lauzier, Francois, Marshall, John C., Martin, Claudio M., McIntyre, Lauralyn, Muscedere, John, Reynolds, Steven, Sligl, Wendy, Stelfox, Henry T., Wilcox, M. Elizabeth, Fowler, Robert A., and on behalf of the Canadian Critical Care Trials Group
- Published
- 2018
- Full Text
- View/download PDF
6. A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial
- Author
-
Kruger Peter, Cook Deborah J, Fowler Robert, Cuthbertson Brian, Smith Orla, Chant Clarence, Burns Karen EA, Webb Steve, Alhashemi Jamal, Dominguez-Cherit Guillermo, Zala Carlos, Rubenfeld Gordon D, and Marshall John C
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background Swine origin influenza A/H1N1 infection (H1N1) emerged in early 2009 and rapidly spread to humans. For most infected individuals, symptoms were mild and self-limited; however, a small number developed a more severe clinical syndrome characterized by profound respiratory failure with hospital mortality ranging from 10 to 30%. While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments. Multiple observational studies have suggested that HMGCoA reductase inhibitors (statins) can exert a class effect in attenuating inflammation. The Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial sought to investigate the feasibility of conducting a trial during a global pandemic in critically ill patients with H1N1 with the goal of informing the design of a larger trial powered to determine impact of statins on important outcomes. Methods/Design A multi-national, pilot randomized controlled trial (RCT) of once daily enteral rosuvastatin versus matched placebo administered for 14 days for the treatment of critically ill patients with suspected, probable or confirmed H1N1 infection. We propose to randomize 80 critically ill adults with a moderate to high index of suspicion for H1N1 infection who require mechanical ventilation and have received antiviral therapy for ≤ 72 hours. Site investigators, research coordinators and clinical pharmacists will be blinded to treatment assignment. Only research pharmacy staff will be aware of treatment assignment. We propose several approaches to informed consent including a priori consent from the substitute decision maker (SDM), waived and deferred consent. The primary outcome of the CHAT trial is the proportion of eligible patients enrolled in the study. Secondary outcomes will evaluate adherence to medication administration regimens, the proportion of primary and secondary endpoints collected, the number of patients receiving open-label statins, consent withdrawals and the effect of approved consent models on recruitment rates. Discussion Several aspects of study design including the need to include central randomization, preserve allocation concealment, ensure study blinding compare to a matched placebo and the use novel consent models pose challenges to investigators conducting pandemic research. Moreover, study implementation requires that trial design be pragmatic and initiated in a short time period amidst uncertainty regarding the scope and duration of the pandemic. Trial Registration Number ISRCTN45190901
- Published
- 2011
- Full Text
- View/download PDF
7. Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2)
- Author
-
Mullan Rebecca J, Bankhead Clare R, Kaur Jagdeep, Sood Amit, Raatz Heike, Mulla Sohail M, Burns Karen EA, Nordmann Alain J, Lampropulos Julianna F, Bucher Heiner C, Karanicolas Paul J, You John J, Elnour Nisrin, Soares Heloisa P, Kirpalani Haresh, Gwadry-Sridhar Femida, Mills Edward J, Adhikari Neill KJ, Djulbegovic Benjamin, Murad M Hassan, Strahm Brigitte, Elamin Mohamed B, Flynn David N, da Silva Suzana, Culebro Carolina, Kunz Regina, Urrutia Gerard, Alonso-Coello Pablo, Ferreira-Gonzalez Ignacio, Akl Elie A, Malaga German, Glasziou Paul, Bassler Dirk, Montori Victor M, Lane Melanie, Briel Matthias, Nerenberg Kara A, Vandvik Per, Coto-Yglesias Fernando, Schünemann Holger, Tuche Fabio, Chrispim Pedro, Cook Deborah J, Lutz Kristina, Ribic Christine M, Vale Noah, Erwin Patricia J, Perera Rafael, Zhou Qi, Heels-Ansdell Diane, Ramsay Tim, Walter Stephen D, and Guyatt Gordon H
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background Randomized clinical trials (RCTs) stopped early for benefit often receive great attention and affect clinical practice, but pose interpretational challenges for clinicians, researchers, and policy makers. Because the decision to stop the trial may arise from catching the treatment effect at a random high, truncated RCTs (tRCTs) may overestimate the true treatment effect. The Study Of Trial Policy Of Interim Truncation (STOPIT-1), which systematically reviewed the epidemiology and reporting quality of tRCTs, found that such trials are becoming more common, but that reporting of stopping rules and decisions were often deficient. Most importantly, treatment effects were often implausibly large and inversely related to the number of the events accrued. The aim of STOPIT-2 is to determine the magnitude and determinants of possible bias introduced by stopping RCTs early for benefit. Methods/Design We will use sensitive strategies to search for systematic reviews addressing the same clinical question as each of the tRCTs identified in STOPIT-1 and in a subsequent literature search. We will check all RCTs included in each systematic review to determine their similarity to the index tRCT in terms of participants, interventions, and outcome definition, and conduct new meta-analyses addressing the outcome that led to early termination of the tRCT. For each pair of tRCT and systematic review of corresponding non-tRCTs we will estimate the ratio of relative risks, and hence estimate the degree of bias. We will use hierarchical multivariable regression to determine the factors associated with the magnitude of this ratio. Factors explored will include the presence and quality of a stopping rule, the methodological quality of the trials, and the number of total events that had occurred at the time of truncation. Finally, we will evaluate whether Bayesian methods using conservative informative priors to "regress to the mean" overoptimistic tRCTs can correct observed biases. Discussion A better understanding of the extent to which tRCTs exaggerate treatment effects and of the factors associated with the magnitude of this bias can optimize trial design and data monitoring charters, and may aid in the interpretation of the results from trials stopped early for benefit.
- Published
- 2009
- Full Text
- View/download PDF
8. LOST to follow-up Information in Trials (LOST-IT): a protocol on the potential impact
- Author
-
Salazar Arturo, Bassler Dirk, Mills Edward J, Vera Claudio, Johnston Bradley C, Nerenberg Kara A, Sun Xin, Alshurafa Mohamad, Cukierman-Yaffe Tali, Gangji Azim, Lamontagne Francois, You John J, Briel Matthias, Akl Elie A, Bhatnagar Neera, Busse Jason W, Khalid Zara, Walter SD, Cook Deborah J, Schünemann Holger J, Altman Douglas G, and Guyatt Gordon H
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background Incomplete ascertainment of outcomes in randomized controlled trials (RCTs) is likely to bias final study results if reasons for unavailability of patient data are associated with the outcome of interest. The primary objective of this study is to assess the potential impact of loss to follow-up on the estimates of treatment effect. The secondary objectives are to describe, for published RCTs, (1) the reporting of loss to follow-up information, (2) the analytic methods used for handling loss to follow-up information, and (3) the extent of reported loss to follow-up. Methods We will conduct a systematic review of reports of RCTs recently published in five top general medical journals. Eligible RCTs will demonstrate statistically significant effect estimates with respect to primary outcomes that are patient-important and expressed as binary data. Teams of 2 reviewers will independently determine eligibility and extract relevant information from each eligible trial using standardized, pre-piloted forms. To assess the potential impact of loss to follow-up on the estimates of treatment effect we will, for varying assumptions about the outcomes of participants lost to follow-up (LTFU), calculate (1) the percentage of RCTs that lose statistical significance and (2) the mean change in effect estimate across RCTs. The different assumptions we will test are the following: (1) none of the LTFU participants had the event; (2) all LTFU participants had the event; (3) all LTFU participants in the treatment group had the event; none of those in the control group had it (worst case scenario); (4) the event incidence among LTFU participants (relative to observed participants) increased, with a higher relative increase in the intervention group; and (5) the event incidence among LTFU participants (relative to observed participants) increased in the intervention group and decreased in the control group. Discussion We aim to make our objectives and methods transparent. The results of this study may have important implications for both clinical trialists and users of the medical literature.
- Published
- 2009
- Full Text
- View/download PDF
9. A pilot randomized controlled trial of 7 versus 14 days of antibiotic treatment for bloodstream infection on non-intensive care versus intensive care wards.
- Author
-
Daneman, Nick, Rishu, Asgar H., Pinto, Ruxandra, Arabi, Yaseen, Belley-Cote, Emilie P., Cirone, Robert, Downing, Mark, Cook, Deborah J., Hall, Richard, McGuinness, Shay, McIntyre, Lauralyn, Muscedere, John, Parke, Rachael, Reynolds, Steven, Rogers, Benjamin A., Shehabi, Yahya, Shin, Phillip, Whitlock, Richard, Fowler, Robert A., and Canadian Critical Care Trials Group
- Subjects
INTENSIVE care units ,CRITICAL care medicine ,ESCHERICHIA coli diseases ,CANDIDEMIA ,ENTEROCOCCAL infections - Abstract
Background: The optimal treatment duration for patients with bloodstream infection is understudied. The Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) pilot randomized clinical trial (RCT) determined that it was feasible to enroll and randomize intensive care unit (ICU) patients with bloodstream infection to 7 versus 14 days of treatment, and served as the vanguard for the ongoing BALANCE main RCT. We performed this BALANCE-Ward pilot RCT to examine the feasibility and impact of potentially extending the BALANCE main RCT to include patients hospitalized on non-ICU wards.Methods: We conducted an open pilot RCT among a subset of six sites participating in the ongoing BALANCE RCT, randomizing patients with positive non-Staphylococcus aureus blood cultures on non-ICU wards to 7 versus 14 days of antibiotic treatment. The co-primary feasibility outcomes were recruitment rate and adherence to treatment duration protocol. We compared feasibility outcomes, patient/pathogen characteristics, and overall outcomes among those enrolled in this BALANCE-Ward and prior BALANCE-ICU pilot RCTs. We estimated the sample size and non-inferiority margin impacts of expanding the BALANCE main RCT to include non-ICU patients.Results: A total of 134 patients were recruited over 47 site-months (mean 2.9 patients/site-month, median 1.0, range 0.1-4.4 patients/site-month). The overall recruitment rate exceeded the BALANCE-ICU pilot RCT (mean 1.10 patients/site-month, p < 0.0001). Overall protocol adherence also exceeded the adherence in the BALANCE-ICU pilot RCT (125/134, 93% vs 89/115, 77%, p = 0.0003). BALANCE-Ward patients were older, with lower Sequential Organ Failure Assessment scores, and higher proportions of infections caused by Escherichia coli and genito-urinary sources of bloodstream infection. The BALANCE-Ward pilot RCT patients had an overall 90-day mortality rate of 17/133 (12.8%), which was comparable to the 90-day mortality rate in the ICU pilot RCT (17/115, 14.8%) (p = 0.65). Simulation models indicated there would be minimal sample size and non-inferiority margin implications of expanding enrolment to increasing proportions of non-ICU versus ICU patients.Conclusion: It is feasible to enroll non-ICU patients in a trial of 7 versus 14 days of antibiotics for bloodstream infection, and expanding the BALANCE RCT hospital-wide has the potential to improve the timeliness and generalizability of trial results.Trial Registration: Clinicaltrials.gov, NCT02917551. Registered on September 28, 2016. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. Lessening Organ dysfunction with VITamin C (LOVIT): protocol for a randomized controlled trial.
- Author
-
Masse, Marie-Hélène, Ménard, Julie, Sprague, Sheila, Battista, Marie-Claude, Cook, Deborah J., Guyatt, Gordon H., Heyland, Daren K., Kanji, Salmaan, Pinto, Ruxandra, Day, Andrew G., Cohen, Dian, Annane, Djillali, McGuinness, Shay, Parke, Rachael, Carr, Anitra, Arabi, Yaseen, Vijayaraghavan, Bharath Kumar Tirupakuzhi, D'Aragon, Frédérick, Carbonneau, Élaine, and Maslove, David
- Subjects
VITAMIN C ,RANDOMIZED controlled trials ,HOSPITAL admission & discharge ,INTENSIVE care units ,ACUTE kidney failure ,SEPSIS - Abstract
Background: Sepsis is a health problem of global importance; treatments focus on controlling infection and supporting failing organs. Recent clinical research suggests that intravenous vitamin C may decrease mortality in sepsis. We have designed a randomized controlled trial (RCT) to ascertain the effect of vitamin C on the composite endpoint of death or persistent organ dysfunction at 28 days in patients with sepsis.Methods: LOVIT (Lessening Organ dysfunction with VITamin C) is a multicenter, parallel-group, blinded (participants, clinicians, study personnel, Steering Committee members, data analysts), superiority RCT (minimum n = 800). Eligible patients have sepsis as the diagnosis for admission to the intensive care unit (ICU) and are receiving vasopressors. Those admitted to the ICU for more than 24 h are excluded. Eligible patients are randomized to high-dose intravenous vitamin C (50 mg/kg every 6 h for 96 h) or placebo. The primary outcome is a composite of death or persistent organ dysfunction (need for vasopressors, invasive mechanical ventilation, or new and persisting renal replacement therapy) at day 28. Secondary outcomes include persistent organ dysfunction-free days to day 28, mortality and health-related quality of life at 6 months, biomarkers of dysoxia, inflammation, infection, endothelial function, and adverse effects (hemolysis, acute kidney injury, and hypoglycemia). Six subgroup analyses are planned.Discussion: This RCT will provide evidence of the effect of high-dose intravenous vitamin C on patient-important outcomes in patients with sepsis.Trial Registration: clinicaltrials.gov, NCT03680274, first posted 21 September 2018. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
11. Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial-PROSPECT: a pilot trial.
- Author
-
Cook, Deborah J., Johnstone, Jennie, Marshall, John C., Lauzier, Francois, Thabane, Lehana, Mehta, Sangeeta, Dodek, Peter M., McIntyre, Lauralyn, Pagliarello, Joe, Henderson, William, Taylor, Robert W., Cartin-Ceba, Rodrigo, Golan, Eyal, Herridge, Margaret, Wood, Gordon, Ovakim, Daniel, Karachi, Tim, Surette, Michael G., Bowdish, Dawn M. E., and Lamarche, Daphnee
- Subjects
- *
THERAPEUTIC use of probiotics , *PNEUMONIA prevention , *MECHANICAL ventilators , *COMPETITIVE exclusion (Microbiology) , *TRACHEAL diseases , *PNEUMONIA diagnosis , *PNEUMONIA-related mortality , *COMPARATIVE studies , *LENGTH of stay in hospitals , *INTENSIVE care units , *LACTOBACILLUS , *RESEARCH methodology , *MEDICAL cooperation , *PNEUMONIA , *RESEARCH , *TIME , *TRACHEA , *TRACHEA intubation , *PILOT projects , *EVALUATION research , *RANDOMIZED controlled trials , *PROBIOTICS , *TREATMENT effectiveness , *SEVERITY of illness index , *HOSPITAL mortality , *DIAGNOSIS , *VENTILATOR-associated pneumonia , *PREVENTION - Abstract
Background: Probiotics are live microorganisms that may confer health benefits when ingested. Randomized trials suggest that probiotics significantly decrease the incidence of ventilator-associated pneumonia (VAP) and the overall incidence of infection in critically ill patients. However, these studies are small, largely single-center, and at risk of bias. The aim of the PROSPECT pilot trial was to determine the feasibility of conducting a larger trial of probiotics to prevent VAP in mechanically ventilated patients in the intensive care unit (ICU).Methods: In a randomized blinded trial, patients expected to be mechanically ventilated for ≥72 hours were allocated to receive either 1 × 10(10) colony-forming units of Lactobacillus rhamnosus GG or placebo, twice daily. Patients were excluded if they were at increased risk of L. rhamnosus GG infection or had contraindications to enteral medication. Feasibility objectives were: (1) timely recruitment; (2) maximal protocol adherence; (3) minimal contamination; and (4) estimated VAP rate ≥10 %. We also measured other infections, diarrhea, ICU and hospital length of stay, and mortality.Results: Overall, in 14 centers in Canada and the USA, all feasibility goals were met: (1) 150 patients were randomized in 1 year; (2) protocol adherence was 97 %; (3) no patients received open-label probiotics; and (4) the VAP rate was 19 %. Other infections included: bloodstream infection (19.3 %), urinary tract infections (12.7 %), and skin and soft tissue infections (4.0 %). Diarrhea, defined as Bristol type 6 or 7 stools, occurred in 133 (88.7 %) of patients, the median length of stay in ICU was 12 days (quartile 1 to quartile 3, 7-18 days), and in hospital was 26 days (quartile 1 to quartile 3, 14-44 days); 23 patients (15.3 %) died in the ICU.Conclusions: The PROSPECT pilot trial supports the feasibility of a larger trial to investigate the effect of L. rhamnosus GG on VAP and other nosocomial infections in critically ill patients.Trial Registration: Clinicaltrials.gov NCT01782755 . Registered on 29 January 2013. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
12. A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial
- Author
-
Burns, Karen EA, primary, Chant, Clarence, additional, Smith, Orla, additional, Cuthbertson, Brian, additional, Fowler, Robert, additional, Cook, Deborah J, additional, Kruger, Peter, additional, Webb, Steve, additional, Alhashemi, Jamal, additional, Dominguez-Cherit, Guillermo, additional, Zala, Carlos, additional, Rubenfeld, Gordon D, additional, and Marshall, John C, additional
- Published
- 2011
- Full Text
- View/download PDF
13. Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2)
- Author
-
Briel, Matthias, primary, Lane, Melanie, additional, Montori, Victor M, additional, Bassler, Dirk, additional, Glasziou, Paul, additional, Malaga, German, additional, Akl, Elie A, additional, Ferreira-Gonzalez, Ignacio, additional, Alonso-Coello, Pablo, additional, Urrutia, Gerard, additional, Kunz, Regina, additional, Culebro, Carolina Ruiz, additional, da Silva, Suzana Alves, additional, Flynn, David N, additional, Elamin, Mohamed B, additional, Strahm, Brigitte, additional, Murad, M Hassan, additional, Djulbegovic, Benjamin, additional, Adhikari, Neill KJ, additional, Mills, Edward J, additional, Gwadry-Sridhar, Femida, additional, Kirpalani, Haresh, additional, Soares, Heloisa P, additional, Elnour, Nisrin O Abu, additional, You, John J, additional, Karanicolas, Paul J, additional, Bucher, Heiner C, additional, Lampropulos, Julianna F, additional, Nordmann, Alain J, additional, Burns, Karen EA, additional, Mulla, Sohail M, additional, Raatz, Heike, additional, Sood, Amit, additional, Kaur, Jagdeep, additional, Bankhead, Clare R, additional, Mullan, Rebecca J, additional, Nerenberg, Kara A, additional, Vandvik, Per Olav, additional, Coto-Yglesias, Fernando, additional, Schünemann, Holger, additional, Tuche, Fabio, additional, Chrispim, Pedro Paulo M, additional, Cook, Deborah J, additional, Lutz, Kristina, additional, Ribic, Christine M, additional, Vale, Noah, additional, Erwin, Patricia J, additional, Perera, Rafael, additional, Zhou, Qi, additional, Heels-Ansdell, Diane, additional, Ramsay, Tim, additional, Walter, Stephen D, additional, and Guyatt, Gordon H, additional
- Published
- 2009
- Full Text
- View/download PDF
14. LOST to follow-up Information in Trials (LOST-IT): a protocol on the potential impact
- Author
-
Akl, Elie A, primary, Briel, Matthias, additional, You, John J, additional, Lamontagne, Francois, additional, Gangji, Azim, additional, Cukierman-Yaffe, Tali, additional, Alshurafa, Mohamad, additional, Sun, Xin, additional, Nerenberg, Kara A, additional, Johnston, Bradley C, additional, Vera, Claudio, additional, Mills, Edward J, additional, Bassler, Dirk, additional, Salazar, Arturo, additional, Bhatnagar, Neera, additional, Busse, Jason W, additional, Khalid, Zara, additional, Walter, SD, additional, Cook, Deborah J, additional, Schünemann, Holger J, additional, Altman, Douglas G, additional, and Guyatt, Gordon H, additional
- Published
- 2009
- Full Text
- View/download PDF
15. Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): study protocol for a pilot randomized controlled trial.
- Author
-
Daneman, Nick, Rishu, Asgar H., Wei Xiong, Bagshaw, Sean M., Cook, Deborah J., Dodek, Peter, Hall, Richard, Kumar, Anand, Lamontagne, Francois, Lauzier, Francois, Marshall, John C., Martin, Claudio M., McIntyre, Lauralyn, Muscedere, John, Reynolds, Steven, Stelfox, Henry T., and Fowler, Robert A.
- Subjects
CRITICAL care medicine ,CRITICALLY ill ,BACTEREMIA ,ANTI-infective agents ,TREATMENT duration ,MEDICAL care - Abstract
Background: Bacteremia is a leading cause of mortality and morbidity in critically ill adults. No previous randomized controlled trials have directly compared shorter versus longer durations of antimicrobial treatment in these patients. Methods/Design: This is a multicenter pilot randomized controlled trial in critically ill patients with bacteremia. Eligible patients will be adults with a positive blood culture with pathogenic bacteria identified while in the intensive care unit. Eligible, consented patients will be randomized to either 7 days or 14 days of adequate antimicrobial treatment for the causative pathogen(s) detected on blood cultures. The diversity of pathogens and treatment regimens precludes blinding of patient and clinicians, but allocation concealment will be extended to day 7 and outcome adjudicators will be blinded. The primary outcome for the main trial will be 90-day mortality. The primary outcome for the pilot trial is feasibility defined by (i) rate of recruitment exceeding 1 patient per site per month and (ii) adherence to treatment duration protocol = 90%. Secondary outcomes include intensive care unit, hospital and 90-day mortality rates, relapse rates of bacteremia, antibiotic-related side effects and adverse events, rates of Clostridium difficile infection, rates of secondary infection or colonization with antimicrobial resistant organisms, ICU and hospital lengths of stay, mechanical ventilation and vasopressor duration in intensive care unit, and procalcitonin levels on the day of randomization, and day 7, 10 and 14 after the index blood culture. Discussion: The BALANCE pilot trial will inform the design and execution of the subsequent BALANCE main trial, which will evaluate shorter versus longer duration treatment for bacteremia in critically ill patients, and thereby provide an evidence basis for treatment duration decisions for these infections. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.